Cormedix Inc (NAS:CRMD)
$ 5.12 0.01 (0.2%) Market Cap: 281.39 Mil Enterprise Value: 223.47 Mil PE Ratio: 0 PB Ratio: 4.85 GF Score: 54/100

Q4 2019 CorMedix Inc Earnings Call Transcript

Mar 16, 2020 / 08:30PM GMT
Release Date Price: $3.01 (-23.99%)
Operator

Greetings. Welcome to the CorMedix Inc. Fourth Quarter and Fiscal Year 2019 Earnings Call. (Operator Instructions) Please note, this conference is being recorded. I will now turn the conference over to your host, Dan Ferry. You may begin.

Daniel Ferry
LifeSci Advisors, LLC - MD & Relationship Manager

Leading the call today is Khoso Baluch, Chief Executive Officer of CorMedix. He is joined by Phoebe Mounts, Executive Vice President and General Counsel.

Before we begin, I would like to remind everyone that during the call, management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include, but are not limited to, any of the following. Any statements other than statements of historical fact regarding management's expectations, beliefs, goals and plans about the company's prospects, including its clinical development program for Neutrolin in the U.S. and other product candidates, future

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot